首页> 外文期刊>Clinical Pharmacology and Therapeutics >Warfarin-amiodarone drug-drug interactions: Determination of [I] u/K I,u for amiodarone and its plasma metabolites
【24h】

Warfarin-amiodarone drug-drug interactions: Determination of [I] u/K I,u for amiodarone and its plasma metabolites

机译:华法林-胺碘酮药物-药物相互作用:胺碘酮及其血浆代谢物的[I] u / K I,u的测定

获取原文
获取原文并翻译 | 示例
           

摘要

A retrospective clinical evaluation in a cohort of 73 patients receiving stable anticoagulation therapy showed that the addition/elimination of amiodarone resulted in a 6-65% change in warfarin dose requirement. To evaluate the roles of amiodarone and its circulating metabolites in this highly variable inhibitory drug interaction, a liquid chromatography-electrospray ionization-tandem mass spectrometry assay was developed for the quantitation of low concentrations of these compounds in human plasma, using newly synthesized deuterated analogs as internal standards. Inhibition constant (K I) values were determined for the inhibition of (S)-warfarin 7-hydroxylation in human liver microsomes by the parent drug and its metabolites, and the unbound drug fractions (f u) were measured in order to calculate the ratio of unbound plasma concentration to the microsomal K I for the unbound drug (I u/K I,u). From these ratios, we predict that a minor metabolite of amiodarone, namely, N,N-didesethylamiodarone (DDEA), is a major contributor to the interaction between warfarin and amiodarone.
机译:一项对73名接受稳定抗凝治疗的患者进行的回顾性临床评估显示,胺碘酮的添加/消除导致华法林剂量需求发生6-65%的变化。为了评估胺碘酮及其循环代谢物在这种高度可变的抑制药物相互作用中的作用,使用新合成的氘代类似物作为液相色谱-电喷雾电离-串联质谱分析法,用于定量测定人血浆中这些化合物的低浓度。内部标准。确定母体药物及其代谢物对人肝微粒体对(S)-华法林7-羟基化的抑制作用的抑制常数(KI)值,并测量未结合的药物级分(fu),以计算未结合的比例血浆中未结合药物的微粒体KI浓度(I u / KI,u)。从这些比率,我们预测胺碘酮的次要代谢产物,即N,N-二去乙基乙基胺碘酮(DDEA),是华法林与胺碘酮之间相互作用的主要贡献者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号